儿童呼吸系统疾病抗IgE治疗的最新进展
An Update on Anti-IgE Therapy in Pediatric Respiratory Diseases.
作者信息
Licari Amelia, Castagnoli Riccardo, Panfili Elisa, Marseglia Alessia, Brambilla Ilaria, Marseglia Gian Luigi
机构信息
Department of Pediatrics, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy.
Institute of Paediatrics, Department of Biomedical and Surgical Specialties, University of Perugia, Perugia, Italy.
出版信息
Curr Respir Med Rev. 2017 Mar;13(1):22-29. doi: 10.2174/1573398X13666170616110738.
Abstract
Anti-IgE treatment represents a major breakthrough in the therapeutic management of severe allergic asthma. Omalizumab is the unique biologic treatment registered for asthma therapy in children. The clinical efficacy and safety of omalizumab treatment in the pediatric population has been extensively documented in specific trials and consistently expanded from real-life studies. In addition, new experimental evidence suggests that omalizumab may also interfere with the cellular and molecular mechanisms underlying airway remodeling. Novel investigational anti-IgE monoclonal antibodies with improved pharmacodynamic properties are in the pipeline, potentially offering alternative mechanisms of modulating IgE pathway. The aim of this review is to update current knowledge on anti-IgE therapy in pediatric respiratory diseases.
摘要
抗IgE治疗是重度过敏性哮喘治疗管理方面的一项重大突破。奥马珠单抗是唯一获批用于儿童哮喘治疗的生物制剂。奥马珠单抗治疗在儿科人群中的临床疗效和安全性已在特定试验中得到广泛记录，并且在真实世界研究中持续得到拓展。此外，新的实验证据表明奥马珠单抗可能还会干扰气道重塑的细胞和分子机制。具有改善药效学特性的新型抗IgE单克隆抗体正在研发中，有望提供调节IgE通路的替代机制。本综述的目的是更新有关儿科呼吸系统疾病抗IgE治疗的现有知识。
相似文献
1
An Update on Anti-IgE Therapy in Pediatric Respiratory Diseases.儿童呼吸系统疾病抗IgE治疗的最新进展
Curr Respir Med Rev. 2017 Mar;13(1):22-29. doi: 10.2174/1573398X13666170616110738.
2
Pharmacokinetics, Pharmacodynamics, and Safety of MEDI4212, an Anti-IgE Monoclonal Antibody, in Subjects with Atopy: A Phase I Study.抗IgE单克隆抗体MEDI4212在特应性受试者中的药代动力学、药效学及安全性：一项I期研究
Adv Ther. 2016 Feb;33(2):225-51. doi: 10.1007/s12325-016-0287-8. Epub 2016 Feb 3.
3
A recombinant humanized anti-IgE monoclonal antibody (omalizumab) in the therapy of moderate-to-severe allergic asthma.重组人源化抗IgE单克隆抗体（奥马珠单抗）治疗中重度过敏性哮喘
Recent Pat Inflamm Allergy Drug Discov. 2007 Nov;1(3):225-31. doi: 10.2174/187221307782418900.
4
Omalizumab: anti-IgE monoclonal antibody E25, E25, humanised anti-IgE MAb, IGE 025, monoclonal antibody E25, Olizumab, Xolair, rhuMAb-E25.奥马珠单抗：抗IgE单克隆抗体E25、E25、人源化抗IgE单克隆抗体、IGE 025、单克隆抗体E25、奥立珠单抗、Xolair、重组人源化抗IgE单克隆抗体E25
BioDrugs. 2002;16(5):380-6. doi: 10.2165/00063030-200216050-00009.
5
Anti-IgE monoclonal antibody (omalizumab) in the treatment of atopic asthma and allergic respiratory diseases.抗IgE单克隆抗体（奥马珠单抗）在治疗特应性哮喘和过敏性呼吸道疾病中的应用
Curr Drug Targets Inflamm Allergy. 2004 Sep;3(3):227-9. doi: 10.2174/1568010043343615.
6
Anti-IgE antibodies for the treatment of asthma.用于治疗哮喘的抗IgE抗体。
Curr Opin Pulm Med. 2005 Jan;11(1):27-34. doi: 10.1097/01.mcp.0000147860.83639.30.
7
Role of anti-IgE monoclonal antibody (omalizumab) in the treatment of bronchial asthma and allergic respiratory diseases.抗IgE单克隆抗体（奥马珠单抗）在支气管哮喘和过敏性呼吸道疾病治疗中的作用。
Eur J Pharmacol. 2006 Mar 8;533(1-3):302-7. doi: 10.1016/j.ejphar.2005.12.045. Epub 2006 Feb 7.
8
Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy.奥马珠单抗在过敏性疾病中的抗免疫球蛋白E治疗：抗炎活性和临床疗效的最新进展
Clin Exp Allergy. 2005 Apr;35(4):408-16. doi: 10.1111/j.1365-2222.2005.02191.x.
9
IgE-Related Chronic Diseases and Anti-IgE-Based Treatments.IgE 相关的慢性疾病和抗 IgE 治疗方法。
J Immunol Res. 2016;2016:8163803. doi: 10.1155/2016/8163803. Epub 2016 Dec 21.
10
Treating Moderate-to-Severe Allergic Asthma with a Recombinant Humanized Anti-IgE Monoclonal Antibody (Omalizumab).用重组人源化抗IgE单克隆抗体（奥马珠单抗）治疗中重度过敏性哮喘。
Treat Respir Med. 2006;5(6):393-8. doi: 10.2165/00151829-200605060-00004.
引用本文的文献
1
Inborn errors of immunity with atopic phenotypes in the allergy and immunology clinic: a practical review.过敏与免疫门诊中具有特应性表型的先天性免疫缺陷：实用综述
Curr Opin Allergy Clin Immunol. 2025 Apr 1;25(2):105-114. doi: 10.1097/ACI.0000000000001059. Epub 2025 Feb 13.
2
Mepolizumab in Severe Pediatric Asthma: Certainties and Doubts through a Single-Center Experience and Review of the Literature.美泊利珠单抗治疗重度小儿哮喘：基于单中心经验及文献综述的肯定与疑问
Children (Basel). 2024 Jul 25;11(8):895. doi: 10.3390/children11080895.
3
Successful treatment with Omalizumab of a child affected by Systemic Mastocytosis: clinical and biological implications.奥马珠单抗成功治疗系统性肥大细胞增多症患儿：临床和生物学意义。
Ital J Pediatr. 2023 Jan 13;49(1):6. doi: 10.1186/s13052-022-01402-7.
4
Perspectives in Therapy of Chronic Rhinosinusitis.慢性鼻窦炎的治疗展望
Diagnostics (Basel). 2022 Sep 23;12(10):2301. doi: 10.3390/diagnostics12102301.
5
Novel Lung Growth Strategy with Biological Therapy Targeting Airway Remodeling in Childhood Bronchial Asthma.针对儿童支气管哮喘气道重塑的生物治疗新型肺生长策略
Children (Basel). 2022 Aug 19;9(8):1253. doi: 10.3390/children9081253.
6
Clinical Experience with Anti-IgE Monoclonal Antibody (Omalizumab) in Pediatric Severe Allergic Asthma-A Romanian Perspective.抗IgE单克隆抗体（奥马珠单抗）治疗儿童重度过敏性哮喘的临床经验——罗马尼亚视角
Children (Basel). 2021 Dec 6;8(12):1141. doi: 10.3390/children8121141.
7
Asthma in children and adolescents: the ControL'Asma project.儿童和青少年哮喘：ControL'Asma 项目。
Acta Biomed. 2020 Sep 15;91(11-S):e2020002. doi: 10.23750/abm.v91i11-S.10295.
8
AllergoOncology: ultra-low IgE, a potential novel biomarker in cancer-a Position Paper of the European Academy of Allergy and Clinical Immunology (EAACI).过敏肿瘤学：超低免疫球蛋白E，癌症中一种潜在的新型生物标志物——欧洲变态反应和临床免疫学会（EAACI）立场文件
Clin Transl Allergy. 2020 Jul 17;10:32. doi: 10.1186/s13601-020-00335-w. eCollection 2020.
9
Novel therapeutic targets for allergic airway disease in children.儿童过敏性气道疾病的新型治疗靶点
Drugs Context. 2019 Jul 9;8:212590. doi: 10.7573/dic.212590. eCollection 2019.
10
Physalis peruviana L. inhibits ovalbumin‑induced airway inflammation by attenuating the activation of NF‑κB and inflammatory molecules.藜科植物秘鲁酸浆通过抑制 NF-κB 和炎症分子的激活来抑制卵清蛋白诱导的气道炎症。
Int J Mol Med. 2019 Apr;43(4):1830-1838. doi: 10.3892/ijmm.2019.4110. Epub 2019 Feb 26.
本文引用的文献
1
Case series of omalizumab for allergic bronchopulmonary aspergillosis in cystic fibrosis patients.针对囊性纤维化患者过敏性支气管肺曲霉病的奥马珠单抗病例系列。
Pediatr Pulmonol. 2017 Feb;52(2):190-197. doi: 10.1002/ppul.23612. Epub 2016 Oct 7.
2
Chronic Rhinosinusitis with Nasal Polyps.伴鼻息肉的慢性鼻-鼻窦炎
J Allergy Clin Immunol Pract. 2016 Jul-Aug;4(4):565-72. doi: 10.1016/j.jaip.2016.04.012.
3
Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses.多种剂量 QGE031（利格司亭）对比奥马珠单抗和安慰剂抑制过敏原诱导的早期哮喘反应的疗效和安全性。
J Allergy Clin Immunol. 2016 Oct;138(4):1051-1059. doi: 10.1016/j.jaci.2016.02.027. Epub 2016 Apr 7.
4
Utility of serum periostin and free IgE levels in evaluating responsiveness to omalizumab in patients with severe asthma.血清骨膜蛋白和游离 IgE 水平在评估奥马珠单抗治疗重度哮喘患者反应性中的作用。
Allergy. 2016 Oct;71(10):1472-9. doi: 10.1111/all.12922. Epub 2016 May 17.
5
Treating IgE-mediated diseases via targeting IgE-expressing B cells using an anti-CεmX antibody.使用抗CεmX抗体靶向表达IgE的B细胞来治疗IgE介导的疾病。
Pediatr Allergy Immunol. 2016 Aug;27(5):446-51. doi: 10.1111/pai.12584. Epub 2016 May 18.
6
A randomized trial of the efficacy and safety of quilizumab in adults with inadequately controlled allergic asthma.一项关于奎利珠单抗治疗成人过敏性哮喘控制不佳患者疗效及安全性的随机试验。
Respir Res. 2016 Mar 18;17:29. doi: 10.1186/s12931-016-0347-2.
7
Anti-IgE Monoclonal Antibody (Omalizumab) in Refractory and Relapsing Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss): Data on Seventeen Patients.抗 IgE 单克隆抗体（奥马珠单抗）治疗难治性和复发性嗜酸性肉芽肿性多血管炎（Churg-Strauss）：17 例患者的数据。
Arthritis Rheumatol. 2016 Sep;68(9):2274-82. doi: 10.1002/art.39663.
8
Pharmacokinetics, Pharmacodynamics, and Safety of MEDI4212, an Anti-IgE Monoclonal Antibody, in Subjects with Atopy: A Phase I Study.抗IgE单克隆抗体MEDI4212在特应性受试者中的药代动力学、药效学及安全性：一项I期研究
Adv Ther. 2016 Feb;33(2):225-51. doi: 10.1007/s12325-016-0287-8. Epub 2016 Feb 3.
9
Emerging drugs for the treatment of perennial allergic rhinitis.治疗常年性变应性鼻炎的新兴药物
Expert Opin Emerg Drugs. 2016;21(1):57-67. doi: 10.1517/14728214.2016.1139082. Epub 2016 Jan 25.
10
Prevalence of confirmed asthma varies in chronic rhinosinusitis subtypes.确诊哮喘的患病率在慢性鼻窦炎各亚型中有所不同。
Int Forum Allergy Rhinol. 2016 Apr;6(4):373-7. doi: 10.1002/alr.21674. Epub 2015 Dec 17.
Zotero 插件